Single User
£3750
PDF
36 pages

Alpha-1 Anti-Trypsin Deficiency Forecast in 9 Major Markets 2016-2026


Alpha-1 Anti-Trypsin (AAT) is an enzyme belonging to the serpin super family, and is also referred to as alpha-1 proteinase inhibitor (A1PI) because it inhibits a wide variety of proteases. AAT protects tissues from enzymes of inflammatory cells, especially neutrophil elastase protein. In its absence (such as in alpha 1-anti-trypsin deficiency), neutrophil elastase is free to break down elastin, which contributes to the elasticity of the lungs. This results in respiratory complications such as COPD (chronic obstructive pulmonary disease) in adults and cirrhosis of the liver in adults or children.

Alpha-1 Anti-Trypsin deficiency (AATD) is an inherited, rare condition that causes a complete or partial reduction in activity of Alpha-1 Anti-Trypsin (AAT) in the blood and lungs which leads to the deposit of excessive abnormal A1AT protein in liver cells.

This report provides the current prevalent population for Alpha-1 Anti-Trypsin across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Alpha-1 Anti-Trypsin have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Key underlying pathologies linked with developing Alpha-1 Anti-Trypsin include:

  • Cirrhosis
  • COPD
  • Lung Cancer
  • Asthma
  • Panniculitis
  • Systemic Vasculitis

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in the global Alpha-1 Anti-Trypsin market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Alpha-1 Anti-Trypsin and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on the Alpha-1 Anti-Trypsin prevalent population.
  • Identify sub-populations within Alpha-1 Anti-Trypsin which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Alpha-1 Anti-Trypsin patients.
Table of Contents
  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key comorbid conditions/Features associated with the disease
  • Methodology for quantification of patient numbers
  • Top-line prevalence for Alpha-1 Antitrypsin Deficiency
  • Features of AATD patients
    • Pi Phenotype
    • Clinical Manifestations of AATD
  • Abbreviations used in the report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix
List of Tables
  • Prevalence of AATD, total (000s)
  • Prevalence of AATD, males (000s)
  • Prevalence of AATD, females (000s)
  • Protease inhibitor (Pi) phenotype of AATD patients, total (000s)
  • AATD patients with Cirrhosis, total (000s)
  • AATD patients with COPD, total (000s)
  • AATD patients with Lung Cancer, total (000s)
  • AATD patients with Asthma, total (000s)
  • AATD patients with Panniculitis, total (000s)
  • AATD patients with Systemic Vasculitis, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of AATD by 5-yr age cohort, males (000s)
  • USA Prevalence of AATD by 5-yr age cohort, females (000s)
  • France Prevalence of AATD by 5-yr age cohort, males (000s)
  • France Prevalence of AATD by 5-yr age cohort, females (000s)
  • Germany Prevalence of AATD by 5-yr age cohort, males (000s)
  • Germany Prevalence of AATD by 5-yr age cohort females (000s)
  • Italy Prevalence of AATD by 5-yr age cohort, males (000s)
  • Italy Prevalence of AATD by 5-yr age cohort, females (000s)
  • Spain Prevalence of AATD by 5-yr age cohort, males (000s)
  • Spain Prevalence of AATD by 5-yr age cohort, females (000s)
  • UK Prevalence of AATD by 5-yr age cohort, males (000s)
  • UK Prevalence of AATD by 5-yr age cohort, females (000s)
  • Brazil Prevalence of AATD by 5-yr age cohort, males (000s)
  • Brazil Prevalence of AATD by 5-yr age cohort, females (000s)
  • Japan Prevalence of AATD by 5-yr age cohort, males (000s)
  • Japan Prevalence of AATD by 5-yr age cohort, females (000s)
  • India Prevalence of AATD by 5-yr age cohort, males (000s)
  • India Prevalence of AATD by 5-yr age cohort, females (000s)
Brazil, France, Germany, India, Italy, Japan, Spain, United Kingdom, United States of America